A Phase 1/2 interventional study of Ibrutinib in Graft Versus Host Disease, sponsored by Pharmacyclics LLC.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-11.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome — none open to participants now, 1 under way, 1 of them phase 3. ibrutinib · Bronchiolitis Obliterans Syndrome.
Among the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 1/2, and was the 3rd registered.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
Browse Bronchiolitis Obliterans Syndrome studies →None of the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome is open now. The open studies under Bronchiolitis Obliterans Syndrome, anywhere →
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 3
First in 2012; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is close to the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.
Median enrollment 19 across the 11 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 8 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
AbbVie has 9 studies filed under Bronchiolitis Obliterans Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies testing ibrutinib in Bronchiolitis Obliterans Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
This study's enrollment of 45 is close to the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.
Browse Bronchiolitis Obliterans Syndrome studies →Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
First submitted before Pharmacyclics LLC. became part of AbbVie.
Compared within Bronchiolitis Obliterans Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Graft vs Host Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive daily dose of 420 mg of Ibrutinib capsules
Drug: Ibrutinib
Subjects receive daily dose of 280 mg of Ibrutinib capsules
Drug: Ibrutinib
Subjects receive daily dose of 140 mg of Ibrutinib capsules
Drug: Ibrutinib
Subjects receive daily dose of recommended phase 2 dose
Drug: Ibrutinib
Also known as: PCI32765
Phase 1b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD.
Number of participants with dose-limiting toxicities as a measure of safety profile to determine recommended dose of ibrutinib
Time frame: 28 treatment days after last subject enrolled in Phase 1 dose level(s).
Phase 2: Overall Response Rate as the Percentage of Participants With Response
Overall Response Rate is defined as the proportion of subjects who achieved complete response (CR) or partial response (PR). Response criteria are based on NIH cGVHD Response assessment (Pavletic 2006; Measurement of Therapeutic Response, ASBMT Web site).
Time frame: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
Sustained Response Rate as the Percentage of Participants With Sustained Response
For subjects who achieved an NIH-defined CR or PR, the proportion of subjects who achieved CR or PR that was sustained for at least 20 weeks (140 days). Intermittent SD was also acceptable.
Time frame: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
To Evaluate the Clinical Efficacy of Ibrutinib in Steroid Dependent/Refractory cGVHD by Measuring: Duration of Response (DOR)
For subjects who achieved an NIH-defined CR or PR, the interval between the date of initial documentation of a response and the date of first documented evidence of PD, death, or date of censoring if applicable.
Time frame: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
Corticosteroid Requirement Changes Over Time
Average daily corticosteroid dose assessed each week.
Time frame: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Summary Score
Subject reported improvement in symptom burden. The symptom burden will be measured according to the Lee cGVHD Symptom Scale. A change in \>7 points on the Lee cGVHD Symptom Scale will be considered significant and relates to improvement in quality of life. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. A total summary score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores. There are 7 subscales (Skin, Energy, Lung, Eye, Nutrition, Mouth and Psychological) with ratings as follow: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely; with a lower values representing a better outcome.
Time frame: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
Phase 2b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD
Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib
Time frame: From first dose with study drug until 30 days after the last dose of study drug, up to 36.7 months
| Milestone | Phase 1b/Phase 2 |
|---|---|
| Started | 42 |
| All-treated population | 42 |
| Completed | 0 |
| Not completed | 42 |
| Withdrew: Cgvhd progression | 5 |
| Withdrew: Malignancy progression/relapse | 2 |
| Withdrew: Adverse event | 15 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Physician decision | 4 |
| Withdrew: Study terminated by sponsor | 7 |
| Withdrew: Noncompliance with study drug | 2 |
Number of participants with dose-limiting toxicities as a measure of safety profile to determine recommended dose of ibrutinib
| Participants | Phase 1b: Dose Level 1 | Phase 2 |
|---|---|---|
| Phase 1b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD. | 0 | — |
Overall Response Rate is defined as the proportion of subjects who achieved complete response (CR) or partial response (PR). Response criteria are based on NIH cGVHD Response assessment (Pavletic 2006; Measurement of Therapeutic Response, ASBMT Web site).
| percentage of participants | Phase1b/Phase 2 |
|---|---|
| Phase 2: Overall Response Rate as the Percentage of Participants With Response | 69 (52.9 to 82.4) |
For subjects who achieved an NIH-defined CR or PR, the proportion of subjects who achieved CR or PR that was sustained for at least 20 weeks (140 days). Intermittent SD was also acceptable.
| percentage of participants | Phase1b/Phase 2 |
|---|---|
| Sustained Response Rate as the Percentage of Participants With Sustained Response | 69 (49.2 to 84.7) |
For subjects who achieved an NIH-defined CR or PR, the interval between the date of initial documentation of a response and the date of first documented evidence of PD, death, or date of censoring if applicable.
| Median | Phase1b/Phase 2 |
|---|---|
| To Evaluate the Clinical Efficacy of Ibrutinib in Steroid Dependent/Refractory cGVHD by Measuring: Duration of Response (DOR) | NA (NA to NA) |
Average daily corticosteroid dose assessed each week.
| Daily Dose of Steroid by Weight (mg/kg/d | Phase 1b/Phase 2 |
|---|---|
| Week 1 | 0.31 (0.06 to 1.3) |
| Week 2 | 0.32 (0.06 to 1.35) |
| Week 3 | 0.32 (0.06 to 1.35) |
| Week 4 | 0.31 (0.06 to 1.35) |
| Week 5 | 0.31 (0.06 to 1.53) |
| Week 6 | 0.30 (0.06 to 1.53) |
| Week 7 | 0.30 (0.06 to 1.53) |
| Week 8 | 0.30 (0.01 to 1.53) |
| Week 9 | 0.27 (0.00 to 1.03) |
| Week 10 | 0.25 (0.00 to 1.54) |
| Week 11 | 0.25 (0.00 to 2.02) |
| Week 12 | 0.25 (0.00 to 0.62) |
| Week 13 | 0.24 (0.00 to 0.62) |
| Week 14 | 0.23 (0.00 to 0.57) |
| Week 15 | 0.23 (0.00 to 0.58) |
| Week 16 | 0.23 (0.00 to 0.48) |
| Week 17 | 0.21 (0.00 to 0.47) |
| Week 18 | 0.20 (0.00 to 0.44) |
| Week 19 | 0.20 (0.00 to 0.44) |
| Week 20 | 0.21 (0.00 to 0.44) |
| Week 21 | 0.22 (0.00 to 0.37) |
| Week 22 | 0.22 (0.00 to 0.37) |
| Week 23 | 0.22 (0.00 to 0.60) |
| Week 24 | 0.21 (0.00 to 0.37) |
| Week 25 | 0.19 (0.00 to 0.38) |
| Week 26 | 0.18 (0.00 to 0.37) |
| Week 27 | 0.18 (0.00 to 0.37) |
| Week 28 | 0.18 (0.00 to 0.37) |
| Week 29 | 0.16 (0.00 to 0.37) |
| Week 30 | 0.16 (0.00 to 0.32) |
| Week 31 | 0.16 (0.00 to 0.29) |
| Week 32 | 0.18 (0.00 to 0.29) |
| Week 33 | 0.17 (0.00 to 0.29) |
| Week 34 | 0.17 (0.00 to 0.29) |
| Week 35 | 0.18 (0.00 to 0.29) |
| Week 36 | 0.18 (0.00 to 0.29) |
| Week 37 | 0.16 (0.00 to 0.29) |
| Week 38 | 0.15 (0.00 to 0.35) |
| Week 39 | 0.15 (0.00 to 0.30) |
| Week 40 | 0.15 (0.00 to 0.30) |
| Week 41 | 0.15 (0.00 to 0.30) |
| Week 42 | 0.15 (0.00 to 0.30) |
| Week 43 | 0.13 (0.00 to 0.30) |
| Week 44 | 0.13 (0.00 to 0.21) |
| Week 45 | 0.13 (0.00 to 0.21) |
| Week 46 | 0.13 (0.00 to 0.60) |
| Week 47 | 0.13 (0.00 to 0.60) |
| Week 48 | 0.13 (0.00 to 0.53) |
| Week 49 | 0.12 (0.00 to 0.46) |
| Week 50 | 0.10 (0.00 to 0.36) |
| Week 51 | 0.10 (0.00 to 0.24) |
| Week 52 | 0.10 (0.00 to 0.24) |
| Week 53 | 0.10 (0.00 to 0.24) |
| Week 54 | 0.10 (0.00 to 0.24) |
| Week 55 | 0.10 (0.00 to 0.24) |
| Week 56 | 0.10 (0.00 to 0.24) |
| Week 57 | 0.10 (0.00 to 0.24) |
| Week 58 | 0.10 (0.00 to 0.21) |
| Week 59 | 0.10 (0.00 to 0.27) |
| Week 60 | 0.08 (0.00 to 0.21) |
| Week 61 | 0.08 (0.00 to 0.21) |
| Week 62 | 0.08 (0.00 to 0.21) |
| Week 63 | 0.08 (0.00 to 0.21) |
| Week 64 | 0.08 (0.00 to 0.21) |
| Week 65 | 0.08 (0.00 to 0.21) |
| Week 66 | 0.08 (0.00 to 0.21) |
| Week 67 | 0.08 (0.00 to 0.21) |
| Week 68 | 0.08 (0.00 to 0.21) |
| Week 69 | 0.08 (0.00 to 0.21) |
| Week 70 | 0.08 (0.00 to 0.21) |
| Week 71 | 0.07 (0.00 to 0.21) |
| Week 72 | 0.08 (0.00 to 0.21) |
| Week 73 | 0.08 (0.00 to 0.21) |
| Week 74 | 0.07 (0.00 to 0.21) |
| Week 75 | 0.07 (0.00 to 0.20) |
| Week 76 | 0.07 (0.00 to 0.20) |
| Week 77 | 0.07 (0.00 to 0.20) |
| Week 78 | 0.07 (0.00 to 0.20) |
| Week 79 | 0.07 (0.00 to 0.20) |
| Week 80 | 0.07 (0.00 to 0.20) |
| Week 81 | 0.07 (0.00 to 0.27) |
| Week 82 | 0.07 (0.00 to 0.31) |
| Week 83 | 0.07 (0.00 to 0.31) |
| Week 84 | 0.07 (0.00 to 0.31) |
| Week 85 | 0.08 (0.00 to 0.31) |
| Week 86 | 0.08 (0.00 to 0.32) |
| Week 87 | 0.08 (0.00 to 0.32) |
| Week 88 | 0.08 (0.00 to 0.32) |
| Week 89 | 0.08 (0.00 to 0.95) |
| Week 90 | 0.08 (0.00 to 0.95) |
| Week 91 | 0.08 (0.00 to 0.95) |
| Week 92 | 0.08 (0.00 to 0.95) |
| Week 93 | 0.08 (0.00 to 0.95) |
| Week 94 | 0.08 (0.00 to 0.95) |
| Week 95 | 0.08 (0.00 to 0.95) |
| Week 96 | 0.08 (0.00 to 0.95) |
| Week 97 | 0.08 (0.00 to 0.95) |
| Week 98 | 0.08 (0.00 to 0.95) |
| Week 99 | 0.08 (0.00 to 0.95) |
| Week 100 | 0.08 (0.00 to 0.95) |
| Week 101 | 0.09 (0.00 to 0.95) |
| Week 102 | 0.09 (0.00 to 0.95) |
| Week 103 | 0.09 (0.00 to 0.95) |
| Week 104 | 0.09 (0.00 to 0.95) |
| Week 105 | 0.08 (0.00 to 0.95) |
| Week 106 | 0.08 (0.00 to 0.95) |
| Week 107 | 0.08 (0.00 to 0.95) |
| Week 108 | 0.08 (0.00 to 0.95) |
| Week 109 | 0.08 (0.00 to 0.95) |
| Week 110 | 0.08 (0.00 to 0.95) |
| Week 111 | 0.08 (0.00 to 0.95) |
| Week 112 | 0.08 (0.00 to 0.95) |
| Week 113 | 0.08 (0.00 to 0.95) |
| Week 114 | 0.08 (0.00 to 0.95) |
| Week 115 | 0.12 (0.00 to 0.95) |
| Week 116 | 0.12 (0.00 to 0.95) |
| Week 117 | 0.08 (0.00 to 0.95) |
| Week 118 | 0.08 (0.00 to 0.95) |
| Week 119 | 0.08 (0.00 to 0.95) |
| Week 120 | 0.08 (0.00 to 0.95) |
| Week 121 | 0.08 (0.00 to 0.95) |
| Week 122 | 0.12 (0.00 to 0.95) |
| Week 123 | 0.08 (0.00 to 0.22) |
| Week 124 | 0.08 (0.00 to 0.22) |
| Week 125 | 0.08 (0.00 to 0.22) |
| Week 126 | 0.08 (0.00 to 0.22) |
| Week 127 | 0.08 (0.00 to 0.22) |
| Week 128 | 0.00 (0.00 to 0.22) |
| Week 129 | 0.00 (0.00 to 0.22) |
| Week 130 | 0.00 (0.00 to 0.22) |
| Week 131 | 0.00 (0.00 to 0.19) |
| Week 132 | 0.00 (0.00 to 0.15) |
| Week 133 | 0.00 (0.00 to 0.15) |
| Week 134 | 0.00 (0.00 to 0.15) |
| Week 135 | 0.00 (0.00 to 0.15) |
| Week 136 | 0.00 (0.00 to 0.15) |
| Week 137 | 0.00 (0.00 to 0.15) |
| Week 138 | 0.00 (0.00 to 0.15) |
| Week 139 | 0.00 (0.00 to 0.15) |
| Week 140 | 0.00 (0.00 to 0.15) |
| Week 141 | 0.00 (0.00 to 0.16) |
| Week 142 | 0.00 (0.00 to 0.17) |
| Week 143 | 0.00 (0.00 to 0.17) |
| Week 144 | 0.00 (0.00 to 0.17) |
| Week 145 | 0.00 (0.00 to 0.17) |
| Week 146 | 0.00 (0.00 to 0.17) |
| Week 147 | 0.00 (0.00 to 0.17) |
| Week 148 | 0.00 (0.00 to 0.17) |
| Week 149 | 0.00 (0.00 to 0.17) |
| Week 150 | 0.00 (0.00 to 0.17) |
| Week 151 | 0.00 (0.00 to 0.17) |
| Week 152 | 0.00 (0.00 to 0.17) |
| Week 153 | 0.00 (0.00 to 0.15) |
| Week 154 | 0.00 (0.00 to 0.14) |
| Week 155 | 0.00 (0.00 to 0.14) |
| Week 156 | 0.00 (0.00 to 0.14) |
| Week 157 | 0.00 (0.00 to 0.13) |
| Week 158 | 0.06 (0.00 to 0.11) |
| Week 159 | 0.06 (0.00 to 0.11) |
| Week 160 | 0.06 (0.00 to 0.11) |
Subject reported improvement in symptom burden. The symptom burden will be measured according to the Lee cGVHD Symptom Scale. A change in \>7 points on the Lee cGVHD Symptom Scale will be considered significant and relates to improvement in quality of life. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. A total summary score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores. There are 7 subscales (Skin, Energy, Lung, Eye, Nutrition, Mouth and Psychological) with ratings as follow: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely; with a lower values representing a better outcome.
| percentage of participants | Phase 1b/Phase 2 |
|---|---|
| Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Summary Score | 42.9 (27.7 to 59) |
Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib
| Participants | Phase 1b/Phase 2 |
|---|---|
| Phase 2b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD | 42 |
Collected over From first dose of study drug to within 30 days of last dose or starting subsequent therapy for cGVHD, up to 36.7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase1b/Phase 2 | 7/42 (16.7%) | 22/42 (52.4%) | 41/42 (97.6%) |
| Event | Phase1b/Phase 2 |
|---|---|
| PneumoniaRespiratory, thoracic and mediastinal disorders | 6/42 |
| CellulitisInfections and infestations | 2/42 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/42 |
| HeadacheNervous system disorders | 2/42 |
| Septic shockInfections and infestations | 2/42 |
| Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/42 |
| AnaemiaBlood and lymphatic system disorders | 1/42 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/42 |
| Atrial fibrilationCardiac disorders | 1/42 |
| BacteraemiaInfections and infestations | 1/42 |
| Event | Phase1b/Phase 2 |
|---|---|
| Gastrointestinal disordersGastrointestinal disorders | 38/42 |
| General disorders and administration site conditionsGeneral disorders | 30/42 |
| Infections and infestationsInfections and infestations | 25/42 |
| FatiqueGeneral disorders | 24/42 |
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 20/42 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 19/42 |
| Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 18/42 |
| Blood and lymphatic system disordersBlood and lymphatic system disorders | 17/42 |
| DiarrhoeaGastrointestinal disorders | 17/42 |
| Nervous system disordersNervous system disorders | 17/42 |
Baseline analysis population includes all participants that received at least 1 dose of ibrutinib.
| Age, Categorical(Participants) | Phase 1b/Phase 2 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 35 |
| >=65 years | 7 |
| Age, Continuous(years) | Phase 1b/Phase 2 |
|---|---|
| Mean | 50.5 ± 15.53 |
| Sex: Female, Male(Participants) | Phase 1b/Phase 2 |
|---|---|
| Female | 20 |
| Male | 22 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b/Phase 2 |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 40 |
| Race (NIH/OMB)(Participants) | Phase 1b/Phase 2 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 39 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Phase 1b/Phase 2 |
|---|---|
| United States | 42 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2014 to primary completion in Sep 2017, 38 months.
Results were first posted in Jul 2019, 1 year 9 months after primary completion.
Of 24 phase 1/2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 87. This study's 38 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib
Bronchiolitis Obliterans Syndrome →